Apollo Global Management Ord Shs vs IDEXX Laboratories, Inc. — how do they compare? Apollo Global Management Ord Shs trades at $138.13 (market cap $82.84B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: Apollo Global Management Ord Shs is the larger of the two by market cap, and Apollo Global Management Ord Shs pays a 1.6% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| APO | IDXX | |
|---|---|---|
Market Cap | $82.84B | $46.22B |
Sector | Financials | Health |
52-Week High | $152.70 | $766.68 |
52-Week Low | $100.30 | $526.44 |
Enterprise Value | -$168.65B | $47.12B |
Dividend Yield | 1.6% | — |
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $138.79, up 5.13% today, near its 52-week high. The stock shows a bullish technical trend with strong analyst support, including 23 buy ratings and a consensus price target of $151.50. Recent Q2 2026 earnings of $2.11 per share missed estimates, but revenue growth and record assets under management of $1.05 trillion highlight operational strength. The company continues expanding in AI infrastructure deals, as noted in recent news.
Outlook remains positive given robust fundraising and perpetual capital growth, though risks include expense pressures and market volatility. The high P/E ratio of 49.92 suggests premium valuation, requiring sustained earnings growth to justify upside. Investors should weigh strong institutional sentiment against execution risks in a competitive asset management landscape.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →